{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:06:07Z","timestamp":1789394767236,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for EGFR-mutant advanced non\u2013small cell lung cancer (NSCLC) remains uncertain due to the availability of multiple generations of TKIs and limited head-to-head comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) was conducted comparing first, second, and third-generation EGFR-TKIs in treatment-na\u00efve EGFR-mutant NSCLC. Databases including PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials were searched. Outcomes included overall survival (OS), progression-free survival (PFS), and grade\u2009\u2265\u20093 adverse events (AEs). Hazard ratios (HRs) and odds ratios (ORs) were pooled using a frequentist random-effects NMA. Treatments were ranked using P-scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine RCTs were included for PFS and eight for OS and AEs. For OS, dacomitinib (HR 0.75, 95% CI 0.59\u20130.95) and osimertinib (HR 0.80, 95% CI 0.67\u20130.96) showed significant benefit versus first-generation TKIs. For PFS, all evaluated second- and third-generation TKIs significantly improved PFS, with furmonertinib (HR 0.44, 95% CI 0.34\u20130.57) having the highest P-score. In safety analysis, no EGFR-TKI showed a statistically significant difference in grade\u2009\u2265\u20093 adverse events compared with first-generation TKIs. Although befotertinib and dacomitinib had numerically higher odds, all confidence intervals were wide and crossed the null value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While several EGFR-TKIs improved efficacy over first-generation agents, no single treatment was clearly superior across all efficacy and safety outcomes. Osimertinib showed consistent efficacy, while its safety advantage became evident in the sensitivity analysis excluding FLAURA China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s43046-026-00414-2","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:11:17Z","timestamp":1789391477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-na\u00efve EGFR-mutant advanced non\u2013small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"38","author":[{"given":"Sumit","family":"Mahato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Mudgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seshadri Reddy","family":"Varikasuvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansraj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameema","family":"Thankachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"414_CR1","unstructured":"World Health Organization. Lung cancer: key facts. Geneva: World Health Organization. 2026. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer. (accessed April 2026)."},{"key":"414_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non\u2013small cell lung cancer. Nature. 2018;553:446\u201354.","journal-title":"Nature"},{"key":"414_CR3","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non\u2013small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMap). Am J Cancer Res. 2015;5:2892\u2013911.","journal-title":"Am J Cancer Res"},{"key":"414_CR4","first-page":"172","volume":"87","author":"Y-L Zhang","year":"2016","unstructured":"Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non\u2013small-cell lung cancer: a systematic review and meta analysis. Lung Cancer. 2016;87:172\u20139.","journal-title":"Lung Cancer"},{"key":"414_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JSK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non\u2013small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154\u201362.","journal-title":"J Thorac Oncol"},{"key":"414_CR6","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357.","journal-title":"N Engl J Med"},{"key":"414_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first line treatment for European patients with advanced EGFR mutation positive non\u2013small-cell lung cancer (EURTAC): a multicentre, open label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"414_CR8","first-page":"612","volume":"32","author":"JCH Yang","year":"2014","unstructured":"Yang JCH, Schuler M, Yamamoto N, et al. LUX Lung 3: a randomized, open label, phase III study of afatinib versus cisplatin plus pemetrexed in patients with advanced EGFR mutation positive lung adenocarcinoma. J Clin Oncol. 2014;32:612\u201322.","journal-title":"J Clin Oncol"},{"key":"414_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first line treatment of Asian patients with advanced non small cell lung cancer harboring EGFR mutations (LUX Lung 6): an open label, randomized phase 3 trial. Lancet Oncol. 2014;15:213\u201322.","journal-title":"Lancet Oncol"},{"issue":"5","key":"414_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, et al. Afatinib versus Gefitinib as First-Line Treatment of Patients with EGFR Mutation-Positive NSCLC (LUX-Lung 7). Lancet Oncol. 2016;17(5):577\u201389.","journal-title":"Lancet Oncol"},{"issue":"7","key":"414_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus Gefitinib in Patients with EGFR-Mutated Non-Small-Cell Lung Cancer (ARCHER 1050). N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"414_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"key":"414_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"414_CR14","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2018;29(Suppl 4):iv192\u2013237.","journal-title":"Ann Oncol"},{"key":"414_CR15","first-page":"35623","volume":"8","author":"W Liang","year":"2017","unstructured":"Liang W, Wu X, Fang W, et al. Network meta analysis of first line EGFR TKI treatments for advanced non\u2013small-cell lung cancer harboring EGFR mutations. Oncotarget. 2017;8:35623\u201336.","journal-title":"Oncotarget"},{"key":"414_CR16","first-page":"3409","volume":"10","author":"F Zhou","year":"2018","unstructured":"Zhou F, Zhou C. Network meta analysis of EGFR tyrosine kinase inhibitor\u2013based first line therapies for advanced EGFR mutant non\u2013small-cell lung cancer. Cancer Manag Res. 2018;10:3409\u201318.","journal-title":"Cancer Manag Res"},{"key":"414_CR17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JTO.0000000000000115","volume":"9","author":"S Popat","year":"2014","unstructured":"Popat S, Mok T, Yang JCH, et al. Afatinib, gefitinib, and erlotinib as first line treatment for EGFR mutation\u2013positive non\u2013small-cell lung cancer: a network meta analysis. J Thorac Oncol. 2014;9:631\u201340.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"414_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China. Target Oncol. 2021;16(2):165\u201376.","journal-title":"Target Oncol"},{"issue":"11","key":"414_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454\u201366.","journal-title":"Lancet Oncol"},{"issue":"2","key":"414_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares L, Tan EH, O\u2019Byrne K, Zhang L, Hirsh V, Boyer M, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017;28(2):270\u20137.","journal-title":"Ann Oncol"},{"issue":"27","key":"414_CR21","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu S, Wang Q, Zhang G, Dong X, Yang CT, Kim SW, et al. Aumolertinib versus Gefitinib as First-Line Treatment in EGFR-Mutated Advanced NSCLC (AENEAS). J Clin Oncol. 2022;40(27):3162\u201371.","journal-title":"J Clin Oncol"},{"issue":"25","key":"414_CR22","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.23.00515","volume":"41","author":"BC Cho","year":"2023","unstructured":"Cho BC, Kim DW, Kim SW, Lee JS, Su WC, Ahn JS, et al. Lazertinib versus Gefitinib as First-Line Treatment in EGFR-Mutated Advanced NSCLC (LASER301). J Clin Oncol. 2023;41(25):4208\u201317.","journal-title":"J Clin Oncol"},{"issue":"11","key":"414_CR23","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.jtho.2025.06.030","volume":"20","author":"SH Lee","year":"2025","unstructured":"Lee SH, Lu S, Hayashi H, et al. Lazertinib versus osimertinib in previously untreated EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA. J Thorac Oncol. 2025;20(11):1655\u201368. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.030.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"414_CR24","first-page":"553","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu S, Wu L, Jian H, Cheng Y, Wang Z, Fang J, et al. Befotertinib versus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC. Lancet Respir Med. 2023;11(6):553\u201364.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"414_CR25","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi Y, Zhang L, Liu X, Zhou C, Zhang S, Wang D, et al. Furmonertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC (FURLONG). Lancet Respir Med. 2022;10(11):1019\u201328.","journal-title":"Lancet Respir Med"},{"key":"414_CR26","first-page":"1104563","volume":"13","author":"X Yi\u03bd","year":"2023","unstructured":"Yi\u03bd X, Zh\u03b1\u03bdg Y, Zh\u03b1\u03bdg L, \u03a9\u03b1\u03bdg J, Liu H, Che\u03bd Q. e\u03c4 \u03b1l. Co\u00b5\u03c0\u03b1\u03c1\u03b1\u03c4ive e\u03c6\u03c6ic\u03b1cy \u03b1\u03bd\u03b4 \u03c3\u03b1\u03c6e\u03c4y o\u03c6 \u03c6i\u03c1\u03c3\u03c4-li\u03bde \u03c4\u03c1e\u03b1\u03c4\u00b5e\u03bd\u03c4\u03c3 \u03c6o\u03c1 EG\u03a6R-\u00b5u\u03c4\u03b1\u03bd\u03c4 \u03b1\u03b4v\u03b1\u03bdce\u03b4 \u03bdo\u03bd-\u03c3\u00b5\u03b1ll cell lu\u03bdg c\u03b1\u03bdce\u03c1: \u03b1 \u03bde\u03c4\u03c9o\u03c1k \u00b5e\u03c4\u03b1-\u03b1\u03bd\u03b1ly\u03c3i\u03c3. \u03a6\u03c1o\u03bd\u03c4 O\u03bdcol. 2023;13:1104563.","journal-title":"\u03a6\u03c1o\u03bd\u03c4 O\u03bdcol"},{"key":"414_CR27","first-page":"102315","volume":"102","author":"X Li","year":"2022","unstructured":"Li X, Zhou C, \u03a9u YL, Che\u03bd G, \u03a6e\u03bdg J, Lu S, e\u03c4 \u03b1l. Co\u00b5\u03c0\u03b1\u03c1\u03b1\u03c4ive e\u03c6\u03c6ic\u03b1cy o\u03c6 \u03c6i\u03c1\u03c3\u03c4-li\u03bde \u03c4\u03c1e\u03b1\u03c4\u00b5e\u03bd\u03c4\u03c3 \u03c6o\u03c1 EG\u03a6R-\u00b5u\u03c4\u03b1\u03c4e\u03b4 \u03b1\u03b4v\u03b1\u03bdce\u03b4 NSCLC: \u03b1 \u03bde\u03c4\u03c9o\u03c1k \u00b5e\u03c4\u03b1-\u03b1\u03bd\u03b1ly\u03c3i\u03c3 o\u03c6 \u03c1\u03b1\u03bd\u03b4o\u00b5ize\u03b4 \u03c4\u03c1i\u03b1l\u03c3. C\u03b1\u03bdce\u03c1 T\u03c1e\u03b1\u03c4 Rev. 2022;102:102315.","journal-title":"C\u03b1\u03bdce\u03c1 T\u03c1e\u03b1\u03c4 Rev"},{"issue":"2","key":"414_CR28","first-page":"225","volume":"16","author":"Y Zh\u03b1\u03bdg","year":"2021","unstructured":"Zh\u03b1\u03bdg Y, \u03a6u \u03a6, Che\u03bd H, Liu Y, \u03a9\u03b1\u03bdg H, Zh\u03b1o X. e\u03c4 \u03b1l. Co\u00b5\u03c0\u03b1\u03c1\u03b1\u03c4ive e\u03c6\u03c6ic\u03b1cy \u03b1\u03bd\u03b4 \u03c3\u03b1\u03c6e\u03c4y o\u03c6 EG\u03a6R-TKI\u03c3 \u03c6o\u03c1 \u03c6i\u03c1\u03c3\u03c4-li\u03bde \u03c4\u03c1e\u03b1\u03c4\u00b5e\u03bd\u03c4 o\u03c6 \u03b1\u03b4v\u03b1\u03bdce\u03b4 NSCLC \u03c9i\u03c4h EG\u03a6R \u00b5u\u03c4\u03b1\u03c4io\u03bd\u03c3: \u03b1 \u03bde\u03c4\u03c9o\u03c1k \u00b5e\u03c4\u03b1-\u03b1\u03bd\u03b1ly\u03c3i\u03c3. J Tho\u03c1\u03b1c O\u03bdcol. 2021;16(2):225\u201338.","journal-title":"J Tho\u03c1\u03b1c O\u03bdcol"},{"key":"414_CR29","first-page":"27","volume":"139","author":"YL \u03a9u","year":"2020","unstructured":"\u03a9u YL, Zhou C, Li\u03b1\u00b5 CK, \u03a9u G, Liu X, Zho\u03bdg Ze\u03c4 \u03b1l. \u03a6i\u03c1\u03c3\u03c4-li\u03bde EG\u03a6R-TKI \u03c4\u03c1e\u03b1\u03c4\u00b5e\u03bd\u03c4 i\u03bd \u03b1\u03b4v\u03b1\u03bdce\u03b4 NSCLC: \u03c3y\u03c3\u03c4e\u00b5\u03b1\u03c4ic \u03c1evie\u03c9 \u03b1\u03bd\u03b4 \u03bde\u03c4\u03c9o\u03c1k \u00b5e\u03c4\u03b1-\u03b1\u03bd\u03b1ly\u03c3i\u03c3. Lu\u03bdg C\u03b1\u03bdce\u03c1. 2020;139:27\u201335.","journal-title":"Lu\u03bdg C\u03b1\u03bdce\u03c1"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00414-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:11:21Z","timestamp":1789391481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00414-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00414-2","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"71"}}